<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Ieven, M.</title>
    <link>http://repub.eur.nl/res/aut/12798/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Reliability of nucleic acid amplification methods for detection of Chlamydia trachomatis in urine: results of the first international collaborative quality control study among 96 laboratories (Article)</title>
      <link>http://repub.eur.nl/res/pub/10188/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>The first European Quality Control Concerted Action study was organized to
      assess the ability of laboratories to detect Chlamydia trachomatis in a
      panel of urine samples by nucleic acid amplification tests (NATs). The
      panel consisted of lyophilized urine samples, including three negative,
      two strongly positive, and five weakly positive samples. Ninety-six
      laboratories in 22 countries participated with a total of 102 data sets.
      Of 204 strongly positive samples 199 (97.5%) were correctly reported, and
      of 506 weakly positive samples 466 (92.1%) were correctly reported. In 74
      (72.5%) data sets correct results were reported on all samples, and 17
      data sets (16.7%) showed either one false-negative or one false-positive
      result. In another 11 data sets, two or more incorrect results were
      reported, and two data sets reported a false-positive result on one
      negative sample. The Roche COBAS Amplicor test was performed in 44 (43%)
      data sets, the Abbott LCx assay was performed in 31 (30%) data sets, the
      Roche Amplicor manual assay was performed in 9 (9%) data sets, an in-house
      PCR was performed in 9 (9%) data sets, the Becton Dickinson ProbeTec ET
      assay was performed in 5 (4.9%) data sets, and the GenProbe TMA assay was
      performed in 4 (3.9%) data sets. The results of the Roche Amplicor manual
      (95.6% correct), COBAS Amplicor (97.0%), and Abbott LCx (94.8%) tests were
      comparable (P = 0.48). The results with the in-house PCR, BD ProbeTec ET,
      and GenProbe TMA tests were reported correctly in 88.6, 98, and 92.5% of
      the tests, respectively. Freeze-drying of clinical urine specimens proved
      to be a successful method for generating standardized, stable, and
      easy-to-transport samples for the detection of C. trachomatis by using
      NATs. Although the results, especially the specificity, for this
      proficiency panel were better than most quality control studies,
      sensitivity problems occurred frequently, underlining the need for good
      laboratory practice and reference reagents to monitor the performance of
      these assays.</description>
    </item>
  </channel>
</rss>